Equities Analysts Set Expectations for CRBU Q3 Earnings

Caribou Biosciences, Inc. (NASDAQ:CRBU) – Equities research analysts at Brookline Capital Markets boosted their Q3 2026 earnings per share (EPS) estimates for shares of Caribou Biosciences in a research note issued to investors on Thursday, August 13th. Brookline Capital Markets analyst L. Cann now anticipates that the company will post earnings of ($0.26) per share for the quarter, up from their previous forecast of ($0.48). The consensus estimate for Caribou Biosciences’ current full-year earnings is ($1.15) per share. Brookline Capital Markets also issued estimates for Caribou Biosciences’ Q4 2026 earnings at ($0.43) EPS, FY2026 earnings at ($0.32) EPS, FY2027 earnings at ($1.35) EPS, FY2028 earnings at ($1.96) EPS, FY2029 earnings at ($3.52) EPS and FY2030 earnings at ($4.85) EPS.

Other analysts also recently issued research reports about the company. Bank of America dropped their price objective on Caribou Biosciences from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Friday. Weiss Ratings reissued a “sell (d-)” rating on shares of Caribou Biosciences in a report on Friday, July 17th. Finally, HC Wainwright lifted their price objective on shares of Caribou Biosciences from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $7.75.

Caribou Biosciences Trading Down 0.6%

CRBU stock opened at $1.57 on Tuesday. The firm’s 50-day moving average is $1.68 and its two-hundred day moving average is $1.84. The company has a market capitalization of $155.71 million, a price-to-earnings ratio of -1.45 and a beta of 2.38. Caribou Biosciences has a 52 week low of $1.38 and a 52 week high of $3.54.

Caribou Biosciences (NASDAQ:CRBU) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. The business had revenue of $1.50 million for the quarter, compared to analysts’ expectations of $2.28 million. Caribou Biosciences had a negative net margin of 1,030.42% and a negative return on equity of 89.11%.

Institutional Trading of Caribou Biosciences

A number of hedge funds have recently modified their holdings of the business. CTC Alternative Strategies Ltd. purchased a new stake in Caribou Biosciences in the 1st quarter worth about $29,000. Bronte Capital Management Pty Ltd. acquired a new position in shares of Caribou Biosciences in the 4th quarter valued at about $25,000. Westmount Partners LLC acquired a new stake in shares of Caribou Biosciences during the first quarter worth approximately $37,000. Next Capital Management LLC acquired a new position in Caribou Biosciences in the 2nd quarter valued at approximately $35,000. Finally, Creative Planning purchased a new stake in Caribou Biosciences in the 2nd quarter worth approximately $25,000. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc is a clinical-stage biopharmaceutical company that leverages its proprietary CRISPR-Cas gene-editing platform to develop transformative cell therapies and in vivo treatments for a range of cancers and genetic diseases. The company’s core technology enables precise modification of cellular genomes, allowing the design of engineered T-cell and NK-cell therapies aimed at improving safety, efficacy and persistence in patients with hematologic and solid tumor malignancies. Alongside its oncology portfolio, Caribou is advancing in vivo editing programs targeting monogenic disorders, with initiatives in areas such as Duchenne muscular dystrophy and familial amyloidosis.

Established in 2011 and headquartered in Berkeley, California, Caribou Biosciences was co-founded by Nobel laureate Jennifer Doudna, one of the pioneers of CRISPR gene-editing technology.